These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4831452)

  • 1. [A new determination method of L-dopa in blood (author's transl)].
    Weitbrecht WU; Birg W; Metzel E; Mundinger F
    Med Klin; 1974 Mar; 69(12):500-1. PubMed ID: 4831452
    [No Abstract]   [Full Text] [Related]  

  • 2. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of parkinsonism using a combination of L-dopa and decarboxylase inhibitor].
    Völler GW; Muschard F
    Med Welt; 1973 Apr; 24(17):705-7. PubMed ID: 4750934
    [No Abstract]   [Full Text] [Related]  

  • 4. [Dopa metabolism in relation to the therapy of Parkinson's syndrome].
    Pletscher A; Bartholini G
    Actual Pharmacol (Paris); 1971; 24():27-49. PubMed ID: 5150621
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 7. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
    Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
    [No Abstract]   [Full Text] [Related]  

  • 8. Experimental evaluation of L-dopa penetration in brain.
    De la Torre JC; Mullan S
    Trans Am Neurol Assoc; 1971; 96():227-9. PubMed ID: 5159088
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dopa resorption and dopamin estimation in blood of patients with Parkinson's disease (author's transl)].
    Metzel E; Weitbrecht WU
    Arch Psychiatr Nervenkr (1970); 1974; 219(3):231-7. PubMed ID: 4433233
    [No Abstract]   [Full Text] [Related]  

  • 10. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
    Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
    Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
    [No Abstract]   [Full Text] [Related]  

  • 12. [Medical treatment of Parkinson's disease].
    Castaigne P; Rondot P; Ribadeau-Dumas JL
    Ann Med Interne (Paris); 1972 Apr; 123(4):357-64. PubMed ID: 5077040
    [No Abstract]   [Full Text] [Related]  

  • 13. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 15. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J; Kase JC; Mena I; Palacios E
    Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.
    Rinne UK; Sonninen V; Sirtola T
    Z Neurol; 1972; 202(1):1-20. PubMed ID: 4114458
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].
    Birkmayer W
    Wien Klin Wochenschr; 1969 Sep; 81(39):677-9. PubMed ID: 5344299
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

  • 19. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of Parkinson's disease: L-dopa or stereotaxic technics?].
    Krayenbuhl H; Siegfried J
    Neurochirurgie; 1970; 16(1):71-6. PubMed ID: 4911157
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.